

## **Galmed Pharmaceuticals Third Quarter 2014 Conference Call and Webcast Scheduled for Wednesday, November 12, 2014**

TEL AVIV, Israel, Nov. 5, 2014 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed"), a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones, announced today that it will host a conference call and webcast on Wednesday, November 12, 2014 to discuss results for the period ended September 30, 2014 and to provide an update on current developments with respect to its clinical program for aramchol.

### ***Conference Call & Webcast***

**Wednesday, November 12, 2014, 8:30am Eastern Time/5:30am Pacific Time**

Domestic:	888-287-5563
International:	719-325-2484
Conference ID:	5293623
Webcast:	<a href="http://galmedpharma.investorroom.com/events-and-presentations">http://galmedpharma.investorroom.com/events-and-presentations</a>

*Replay, available until November 26, 2014*

Domestic:	877-870-5176
International:	858-384-5517
Passcode:	5293623

### **About Galmed Pharmaceuticals Ltd.**

Galmed is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel, once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its proprietary first-in-class family of synthetic fatty-acid/bile-acid conjugates, or FABACs. Galmed believes that its product candidate, aramchol, has the potential to be a disease modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-Hepatitis, or NASH, which is a chronic disease that Galmed believes constitutes a large unmet medical need.

### ***Cautionary Note on Forward-Looking Statements***

*This press release includes forward-looking statements. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Applicable risks and uncertainties include those identified under the heading "Risk Factors" included in the registration statement on Form F-1 (File No. 333 -193792), initially filed with the Securities and Exchange Commission, or the SEC, on February 6, 2014 and declared effective by the SEC*

*on March 12, 2014, and in other filings that Galmed has made and may make with the SEC in the future. The forward-looking statements contained in this press release reflect Galmed's current views with respect to future events, and Galmed does not undertake and specifically disclaims any obligation to update any forward-looking statements.*

To view the original version on PR Newswire, visit <http://www.prnewswire.com/news-releases/galmed-pharmaceuticals-third-quarter-2014-conference-call-and-webcast-scheduled-for-wednesday-november-12-2014-360512618.html>

SOURCE Galmed Pharmaceuticals Ltd.

For further information: Andrew McDonald Ph.D., LifeSci Advisors, LLC, 646-597-6987, [andrew@lifesciadvisors.com](mailto:andrew@lifesciadvisors.com); Josh Blacher, Galmed Pharmaceuticals Ltd., [josh@galmedpharma.com](mailto:josh@galmedpharma.com)

---

<https://galmedpharma.investorroom.com/2014-11-05-Galmed-Pharmaceuticals-Third-Quarter-2014-Conference-Call-and-Webcast-Scheduled-for-Wednesday-November-12-2014>